Zhai Li, Tai Wen-Lin, Pan Yu-Qing, Luo Jian-Bo, Ma Li, Zheng Ya-Ting, Guo Meng-Yue, Zhang Xi
Department of Clinical Laboratory, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University Kunming, Yunnan, China.
Department of Clinical Laboratory, Yunnan Molecular Diagnostic Center, The Second Affiliated Hospital of Kunming Medical University Kunming, China.
Int J Clin Exp Pathol. 2020 Mar 1;13(3):456-464. eCollection 2020.
Previous researches have demonstrated that EZH2 expression is increased in many solid tumors and is closely related to the worse progression, transcriptional silence, distal metastasis, and differential inhibition of tumors. P53 can regulate many cells signaling pathways and play an important role in cell cycle, cell apoptosis, and cell senescence. However, there are few reports on the expression of EZH2 and p53 in ovarian cancer and their correlation with the ovarian cancer. The purpose is to elucidate the expression of EZH2 and p53 in ovarian cancer and to study the relationship of EZH2 and p53 with the clinical parameters of ovarian cancer. In this study, both mRNA and protein level of EZH2 in ovarian cancer group was significantly higher than that in borderline, benign, and normal group; while the mRNA and protein level of p53 was significantly lower than that in borderline, benign, and normal group. The expression of EZH2 protein was mainly located in the cytoplasm and nucleus, while mutated p53 protein was mainly located in the nucleus. Furthermore, the expression of EZH2 is closely related to the FIGO stage and histological grade of ovarian cancer. EZH2 and P53 are closely related to the occurrence of ovarian cancer. We speculate that EZH2 may promote the development of ovarian cancer by inhibiting the expression of p53, suggesting that p53 may be the target gene of EZH2.
既往研究表明,EZH2在许多实体瘤中表达增加,且与肿瘤进展更差、转录沉默、远处转移及肿瘤的差异抑制密切相关。P53可调控多种细胞信号通路,在细胞周期、细胞凋亡及细胞衰老中发挥重要作用。然而,关于EZH2和p53在卵巢癌中的表达及其与卵巢癌的相关性报道较少。目的是阐明EZH2和p53在卵巢癌中的表达,并研究EZH2和p53与卵巢癌临床参数的关系。本研究中,卵巢癌组EZH2的mRNA和蛋白水平均显著高于交界性、良性及正常组;而p53的mRNA和蛋白水平显著低于交界性、良性及正常组。EZH2蛋白表达主要位于细胞质和细胞核,而突变型p53蛋白主要位于细胞核。此外,EZH2的表达与卵巢癌的国际妇产科联盟(FIGO)分期及组织学分级密切相关。EZH2和P53与卵巢癌的发生密切相关。我们推测EZH2可能通过抑制p53的表达促进卵巢癌的发展,提示p53可能是EZH2的靶基因。